European Federation of Biotechnology and Elsevier announce launch of biotechnology journal

February 05, 2007

Amsterdam, 5 February 2007 - Elsevier will launch Biotechnology, the Journal, as the official publication of the European Federation of Biotechnology (EFB) in September 2007. Biotechnology, the Journal will be a cross-disciplinary research and review journal aimed at an audience of academic and commercial bioscientists who are interested not only in science but also in its translation and use. The bi-monthly journal will be a platform for peer-reviewed articles and editorial comments related to biotechnology.

Editor-in-Chief of the journal will be John Hodgson who was Editor of Trends in Biotechnology and Senior Editor of Nature Biotechnology. Hodgson is one of the founders of the biotech consultancy firm, Critical I. According to Hodgson, Biotechnology, the Journal will have a global reach in content and subscription base. "It is important for the credibility of Biotechnology, the Journal that it publishes the best in science and reflects technical and political discussion in an entirely international context. The journal will be inclusive, reaching eastward and westward, seeking the excitement and opportunity in the sciences, technologies and businesses behind biotechnology."

The launch of this exciting journal is planned to coincide with the start of ECB13, The European Congress on Biotechnology, which will be held from September 16th - 19th in Barcelona, Spain. EFB Secretary General Christian Suojanen comments, "We are extremely pleased to be able to launch the journal with both John Hodgson and Elsevier as partners. Biotechnology, the Journal, will seek to reflect the EFB's recognition that the boundaries of science and commerce do not stop at the borders of the European Union, and that it is vital that Biotechnology, the Journal provides the global context that our members need. We firmly believe that the journal will be a success and thus aid in serving both our members and the life sciences community as a whole."
-end-
About the European Federation of Biotechnology

Established by European scientists in 1978, the European Federation of Biotechnology (EFB) is Europe's non-profit federation of National Biotechnology Associations, Learned Societies, Universities, Scientific Institutes, Biotech Companies and Individuals, with 225 Institutional Members and 5,000 personal members in 56 countries working to promote biotechnology throughout Europe and beyond.

The mission of EFB is to advance the sustainable and beneficial use of the life sciences, to promote research and innovation at the cutting edge of biotechnology, to provide a forum for interdisciplinary and international cooperation, to improve scientific education and to facilitate an informed dialogue between scientists and the public.

The EFB has 13 Regional Branch Offices across Europe, one in Beijing and another in development in Moscow. The Central Office is located in Barcelona, Spain. www.efb-central.org

Every two years the EFB organizes the European Congress on Biotechnology. The 13th edition takes place in Barcelona 16-19 September 2007. www.ecb13.eu

About Elsevier Society Publishing

Elsevier is committed to building unique, long-lasting relationships to help societies achieve their publishing goals and provide value-added member services. Elsevier partners with more than 500 international learned societies, professional associations and research institutes. To learn more, please visit the Society homepage (http://www.elsevier.com/wps/find/societyhome.societies) on Elsevier.com.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.

Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Elsevier

Related Biotechnology Articles from Brightsurf:

Cyanobacteria as "green" catalysts in biotechnology
Researchers from TU Graz and Ruhr University Bochum show in the journal ACS Catalysis how the catalytic activity of cyanobacteria, also known as blue-green algae, can be significantly increased.

Biotechnology to the rescue of Brussels sprouts
An international team has identified the genes that make these plants resistant to the pathogen that attacks crops belonging to the cabbage family all over the world.

UM professor co-authors report on the use of biotechnology in forests
University of Montana Professor Diana Six is one of 12 authors of a new report that addresses the potential for biotechnology to provide solutions for protecting forest trees from insect and pathogen outbreaks, which are increasing because of climate change and expanded global trade.

Faster genome evolution methods to transform yeast for industrial biotechnology
A research team led by Prof. DAI Junbiao at the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences, in collaboration with Prof.

New innovations in cell-free biotechnology
Professor Michael Jewett's new platform to conduct cell-free protein synthesis could lead to improved quality of manufactured protein therapeutics and biomaterials.

Silk 'micrococoons' could be used in biotechnology and medicine
Microscopic versions of the cocoons spun by silkworms have been manufactured by a team of researchers.

The end of biotechnology as we know it
More than 400 attendees from five continents discussed trends and improvements in biotechnology at the European Summit of Industrial Biotechnology (ESIB) in Graz/Austria and talked many topics like a dehumanized research process.

Biotechnology: A growing field in the developing world
A detailed new report surveys a broad cross-section of biotechnology work across developing countries, revealing steady growth in fields tied to human well-being worldwide.

China releases first report on biotechnology in developing countries
The first report on biotechnology in developing countries revealing an overall picture of their biotechnology growth and competitiveness was released on Nov.

Exclusive: Biotechnology leaders surveyed about impact of Trump presidency
The day following the election of Donald J. Trump as President, a survey of leaders in biotechnology in the United States, conducted by Genetic Engineering & Biotechnology News showed that Trump's presidency will negatively impact NIH research funding as well as STEM education; a plurality said it will also spark a 'brain drain' as foreign-born researchers educated in American universities will be more likely to leave.

Read More: Biotechnology News and Biotechnology Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.